Plasmacytoid dendritic cells lead the charge against tumors

Sonia Jiménez-Baranda, Inês Pires Silva, Nina Bhardwaj

Research output: Contribution to journalComment/debate

3 Scopus citations


Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.

Original languageEnglish
Pages (from-to)481-484
Number of pages4
JournalJournal of Clinical Investigation
Issue number2
StatePublished - Feb 2012
Externally publishedYes


Dive into the research topics of 'Plasmacytoid dendritic cells lead the charge against tumors'. Together they form a unique fingerprint.

Cite this